Novo Nordisk’s long-acting Factor VIII replacement therapy for hemophilia A, turoctocog alfa pegol, is among 14 new products that are up for an opinion by the European Medicines Agency’s drugs evaluation committee, CHMP, this week on potential pan-EU approval.
In addition, the positive opinion that the CHMP issued last month for bluebird bio’s first-of-a-kind gene therapy for transfusion-dependent...








